Alphabet's Isomorphic Labs raised a $5B Series C led by Sequoia and Greenoaks, after raising $2.1B in May and $600M in March 2025, to accelerate clinical trials (Bloomberg)
The venture secured a massive new capital injection to push its ongoing drug discovery initiatives deeper into clinical trials. Venture capital firms Sequoia and Greenoaks led the investment push for the Alphabet-backed company. This latest Series C transaction follows an aggressive fundraising sequence that previously collected $600 million in March 2025 alongside an additional $2.1 billion closed in May.
Key points
Alphabet's drug venture secured substantial external venture backing to advance its clini…: Alphabet's drug venture secured substantial external venture backing to advance its clinical pipeline.
The latest transaction continues a rapid sequence of major fundraising rounds completed t…: The latest transaction continues a rapid sequence of major fundraising rounds completed throughout 2025.
The company successfully raised $2.1 billion in May before closing its Series C round.: The company successfully raised $2.1 billion in May before closing its Series C round.
Sources checked by our analysis pipeline: 1
Nvidia Newsroom: |
Kanishka Singh / Reuters: |
Kai Nicol-Schwarz / CNBC: |
Lingling Wei / Wall Street Journal: |
CNBC: |
New York Times: |
Wall Street Journal: |
Shirin Ghaffary / Bloomberg: |
Emily Goodin / New York Post: |
Scott Helme / Report URI Blog: |
Juli Clover / MacRumors: |
Politico: |
Bloomberg: |
Jeffrey Kampman / Tom's Hardware: |
Reuters: |
Kif Leswing / CNBC: |
Mauro Orru / Wall Street Journal: |
Nate Raymond / Reuters: |
Camila Grigera Naón / Fortune: |
Financial Times: |
Vicky Ge Huang / Wall Street Journal: |
Rafe Rosner-Uddin / Financial Times: |
Matt Stevens / New York Times: |
Associated Press: |
Groundwork Collaborative: |
This is a Techmeme archive page. It shows how the site appeared at 7:15 AM ET, November 17, 2026.
The most current version of the site as always is available at our home page. To view an earlier snapshot click here and then modify the date indicated.
Wall Street researchers are showing increasing confidence in the artificial intelligence developer as fresh coverage points to sustained upside. Multiple firms now envision significant valuation expansion driven by the company's competitive positioning in the enterprise market. This growing institutional endorsement underscores expectations for durable long-term monetization.
Early evaluations of the wearable software under development indicate notable hurdles for Apple as it refines its newest tools. Hands-on testing revealed substantial functional shortcomings alongside concerns regarding user data trade-offs. These emerging capabilities fall short of comparable market alternatives, limiting their practical value for users.